1University of Pisa and University Cardiology Division, Pisa University Hospital, Pisa, Italy;
and 2Fondazione VillaSerena per la Ricerca, Città Sant'Angelo, Pescara, Italy How to best …

Percutaneous coronary intervention (PCI) is considered a relatively safe procedure
associated with low rates of complications, but is inevitably associated with short and mid-to …

Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and
aspirin remains the standard of care for all patients undergoing percutaneous coronary …

Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

Aims Ticagrelor is associated with a lower risk of ischemic events than clopidogrel.
However, it is uncertain whether the benefits of more intensive anti-ischemic therapy …

The assessment of bleeding and ischemic risk is a crucial step in establishing appropriate
composition and duration of dual antiplatelet therapy (DAPT) in patients with acute coronary …

Oral P2Y12 inhibitors are commonly prescribed for cardiovascular disease and include
clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and …

Single antiplatelet therapy represents the cornerstone of thrombosis prevention in
atherosclerotic cardiovascular disease. Dual antiplatelet therapy (DAPT), consisting of …

Dual antiplatelet therapy (DAPT) has remained the cornerstone for management of acute
coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 …

Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among
healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx …